• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PNV
Click for more information
1.97% $1.99

POLYNOVO LIMITED - Announcements

Market Cap $1.699B  ! watchlist Created with Sketch. Add to my watchlist

PolyNovo Limited is an Australia-based medical device company, which is focused on... PolyNovo Limited is an Australia-based medical device company, which is focused on advanced wound care that designs, develops, and manufactures dermal regeneration solutions using its patented NovoSorb biodegradable polymer technology. Its solutions include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. NovoSorb BTM is a synthetic, biodegradable and biocompatible device designed to facilitate the dermis to grow within a patented polyurethane matrix when lost through extensive surgery, trauma or burn. NovoSorb BTM is indicated for use in the management of wounds, including partial and full thickness wounds, pressure ulcers, venous and diabetic ulcers, chronic and vascular ulcers, surgical wounds, trauma wounds and draining wounds. Its development program covers breast sling, hernia, and orthopedic applications. NovoSorb MTX is available in a range of sizes to address acute and chronic dermal wounds and is comprised of a 2mm biodegradable foam with no sealing membrane.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
PNV Additional Success US BTM usePRICE SENSITIVE27/02/17
PNV First BTM patient in USPRICE SENSITIVE23/02/17
PNV Results announcement, App 4D and Half-Year Financial ReportPRICE SENSITIVE21/02/17
PNV South Africa first order for BTMPRICE SENSITIVE17/02/17
PNV Appointment of Joint Company Secretary20/01/17
PNV Appendix 3B28/12/16
PNV First stock purchasePRICE SENSITIVE22/12/16
PNV Change of Director's Interest Notice21/12/16
PNV Change in CFO Company Secretary19/12/16
PNV Appendix 3B12/12/16
PNV PolyNovo's South Africa Market EntryPRICE SENSITIVE08/12/16
PNV Change of Director's Interest Notice22/11/16
PNV Appendix 3B22/11/16
PNV Results of Meeting18/11/16
PNV Chairman's Address to Shareholders18/11/16
PNV Change in substantial holding-PNV.AX 25/10/16
PNV Change of Director's Interest Notice-PNV.AX 14/10/16
PNV New Zealand and Australia Market entry-PNV.AX 10/10/16
PNV Notice of Annual General Meeting/Proxy Form-PNV.AX 10/10/16
PNV Ceasing to be a substantial holder-PNV.AX 10/10/16
PNV Appendix 3B-PNV.AX 05/10/16
PNV US Market Entry-PolyNovo-PNV.AX PRICE SENSITIVE03/10/16
PNV Change of Director's Interest Notice-PNV.AX 16/09/16
PNV Full Year Statutory Accounts and Appendix 4E-PNV.AX PRICE SENSITIVE22/08/16
PNV Appendix 4G-PNV.AX 22/08/16
PNV Financial result guidance-PNV.AX PRICE SENSITIVE08/08/16
PNV Additional BARDA Option Exercised Valued at US$2.4m-PNV.AX PRICE SENSITIVE31/05/16
PNV Trading Halt-PNV.AX PRICE SENSITIVE30/05/16
PNV Change of Director's Interest Notice-PNV.AX 30/05/16
PNV Change in substantial holding-PNV.AX 18/05/16
PNV Successful use of BTM over bone-PNV.AX 18/05/16
PNV Release of shares from escrow-PNV.AX 13/05/16
PNV Principle Investigators Meeting for US Trial-PNV.AX 03/05/16
PNV PolyNovo presents at ASX Finance News Network-PNV.AX 19/04/16
PNV Appendix 3B-PNV.AX 15/04/16
PNV S&P DJ Indices Announces March Quarterly Review11/03/16
PNV Change of Director's Interest Notice23/02/16
PNV Appendix 3B23/02/16
PNV Half Yearly Report and AccountsPRICE SENSITIVE19/02/16
PNV Financial Result GuidancePRICE SENSITIVE12/02/16
PNV Institutional Investors visit PolyNovo11/02/16
PNV Initial Director's Interest Notice28/01/16
PNV Appointment of Non-executive Director27/01/16
PNV Notice under LR 7.1A.4 and 3.10.5A11/01/16
PNV US FDA approvalPRICE SENSITIVE04/01/16
PNV Change in substantial holding29/12/15
PNV PolyNovo's US FDA approvalPRICE SENSITIVE29/12/15
PNV Change in substantial holding24/12/15
PNV Change of Director's Interest Notice23/12/15
PNV Change of Director's Interest Notice23/12/15
PNV Change of Director's Interest Notice23/12/15
PNV Change of Director's Interest Notice23/12/15
PNV Appendix 3B23/12/15
PNV PolyNovo completes acquisition of minoritiesPRICE SENSITIVE22/12/15
PNV Appendix 3B22/12/15
PNV Independent Valuation Report22/12/15
PNV Share Purchase Plan21/12/15
PNV Results of Meeting17/12/15
PNV Chairman's Address to Shareholders17/12/15
PNV Share Purchase Plan (SPP) Offer02/12/15
PNV Addendum to Notice of Annual General Meeting/ Proxy Form02/12/15
PNV Change in substantial holding01/12/15
PNV Appendix 3B and Section 708A Notice01/12/15
PNV Deferral of Annual General Meeting26/11/15
PNV PolyNovo acquires minority interestsPRICE SENSITIVE25/11/15
PNV Investor Presentation25/11/15
PNV Placement and Share Purchase PlanPRICE SENSITIVE25/11/15
PNV Trading HaltPRICE SENSITIVE23/11/15
PNV Change of Director's Interest Notice18/11/15
PNV Appendix 3B18/11/15
PNV Investor Presentation16/11/15
PNV Change of Director's Interest Notice13/11/15
PNV Appendix 3B13/11/15
PNV Dr John Greenwood awarded South Australian of the Year12/11/15
PNV Appendix 3B12/11/15
PNV Appendix 3B11/11/15
PNV Annual Report to shareholders29/10/15
PNV Notice of Annual General Meeting/Proxy Form29/10/15
PNV Company Secretary Appointment/Resignation27/10/15
PNV Final Patient Recruited in Adelaide Burn TrialPRICE SENSITIVE20/10/15
PNV PolyNovo Awarded BARDA Contract for Burns TrialPRICE SENSITIVE29/09/15
PNV Trading HaltPRICE SENSITIVE28/09/15
PNV Investor Presentation01/09/15
PNV Appendix 4G21/08/15
PNV App 4E / Full Year Statutory AccountsPRICE SENSITIVE20/08/15
PNV Financial Result GuidancePRICE SENSITIVE14/08/15
PNV Appendix 3B06/08/15
PNV CEO Long Term Incentives06/08/15
PNV Change in substantial holding04/08/15
PNV Change in substantial holding04/08/15
PNV PNV New timeline for FDA 510(k)02/07/15
PNV Clinical Paper on Patient follow up of PolyNovo BTMPRICE SENSITIVE01/07/15
PNV Change of Director's Interest Notice17/06/15
PNV PolyNovo Burn Trial Receives Ethics Approval at The AlfredPRICE SENSITIVE15/06/15
PNV CE Mark Clinical Trial for BTM in Severe BurnsPRICE SENSITIVE08/05/15
PNV Settlement of AOD9604 Sale07/05/15
PNV PolyNovo Divests AOD9604PRICE SENSITIVE30/04/15
PNV Half Yearly Report and AccountsPRICE SENSITIVE23/02/15
PNV Half Year Financial Result GuidancePRICE SENSITIVE17/02/15
PNV New Chief Executive Officer and Head of Regulatory AffairsPRICE SENSITIVE13/02/15
PNV Additional Success US BTM use
27/02/17PRICE SENSITIVE
PNV First BTM patient in US
23/02/17PRICE SENSITIVE
PNV Results announcement, App 4D and Half-Year Financial Report
21/02/17PRICE SENSITIVE
PNV South Africa first order for BTM
17/02/17PRICE SENSITIVE
PNV Appointment of Joint Company Secretary
20/01/17
PNV Appendix 3B
28/12/16
PNV First stock purchase
22/12/16PRICE SENSITIVE
PNV Change of Director's Interest Notice
21/12/16
PNV Change in CFO Company Secretary
19/12/16
PNV Appendix 3B
12/12/16
PNV PolyNovo's South Africa Market Entry
08/12/16PRICE SENSITIVE
PNV Change of Director's Interest Notice
22/11/16
PNV Appendix 3B
22/11/16
PNV Results of Meeting
18/11/16
PNV Chairman's Address to Shareholders
18/11/16
PNV Change in substantial holding-PNV.AX
25/10/16
PNV Change of Director's Interest Notice-PNV.AX
14/10/16
PNV New Zealand and Australia Market entry-PNV.AX
10/10/16
PNV Notice of Annual General Meeting/Proxy Form-PNV.AX
10/10/16
PNV Ceasing to be a substantial holder-PNV.AX
10/10/16
PNV Appendix 3B-PNV.AX
05/10/16
PNV US Market Entry-PolyNovo-PNV.AX
03/10/16PRICE SENSITIVE
PNV Change of Director's Interest Notice-PNV.AX
16/09/16
PNV Full Year Statutory Accounts and Appendix 4E-PNV.AX
22/08/16PRICE SENSITIVE
PNV Appendix 4G-PNV.AX
22/08/16
PNV Financial result guidance-PNV.AX
08/08/16PRICE SENSITIVE
PNV Additional BARDA Option Exercised Valued at US$2.4m-PNV.AX
31/05/16PRICE SENSITIVE
PNV Trading Halt-PNV.AX
30/05/16PRICE SENSITIVE
PNV Change of Director's Interest Notice-PNV.AX
30/05/16
PNV Change in substantial holding-PNV.AX
18/05/16
PNV Successful use of BTM over bone-PNV.AX
18/05/16
PNV Release of shares from escrow-PNV.AX
13/05/16
PNV Principle Investigators Meeting for US Trial-PNV.AX
03/05/16
PNV PolyNovo presents at ASX Finance News Network-PNV.AX
19/04/16
PNV Appendix 3B-PNV.AX
15/04/16
PNV S&P DJ Indices Announces March Quarterly Review
11/03/16
PNV Change of Director's Interest Notice
23/02/16
PNV Appendix 3B
23/02/16
PNV Half Yearly Report and Accounts
19/02/16PRICE SENSITIVE
PNV Financial Result Guidance
12/02/16PRICE SENSITIVE
PNV Institutional Investors visit PolyNovo
11/02/16
PNV Initial Director's Interest Notice
28/01/16
PNV Appointment of Non-executive Director
27/01/16
PNV Notice under LR 7.1A.4 and 3.10.5A
11/01/16
PNV US FDA approval
04/01/16PRICE SENSITIVE
PNV Change in substantial holding
29/12/15
PNV PolyNovo's US FDA approval
29/12/15PRICE SENSITIVE
PNV Change in substantial holding
24/12/15
PNV Change of Director's Interest Notice
23/12/15
PNV Change of Director's Interest Notice
23/12/15
PNV Change of Director's Interest Notice
23/12/15
PNV Change of Director's Interest Notice
23/12/15
PNV Appendix 3B
23/12/15
PNV PolyNovo completes acquisition of minorities
22/12/15PRICE SENSITIVE
PNV Appendix 3B
22/12/15
PNV Independent Valuation Report
22/12/15
PNV Share Purchase Plan
21/12/15
PNV Results of Meeting
17/12/15
PNV Chairman's Address to Shareholders
17/12/15
PNV Share Purchase Plan (SPP) Offer
02/12/15
PNV Addendum to Notice of Annual General Meeting/ Proxy Form
02/12/15
PNV Change in substantial holding
01/12/15
PNV Appendix 3B and Section 708A Notice
01/12/15
PNV Deferral of Annual General Meeting
26/11/15
PNV PolyNovo acquires minority interests
25/11/15PRICE SENSITIVE
PNV Investor Presentation
25/11/15
PNV Placement and Share Purchase Plan
25/11/15PRICE SENSITIVE
PNV Trading Halt
23/11/15PRICE SENSITIVE
PNV Change of Director's Interest Notice
18/11/15
PNV Appendix 3B
18/11/15
PNV Investor Presentation
16/11/15
PNV Change of Director's Interest Notice
13/11/15
PNV Appendix 3B
13/11/15
PNV Dr John Greenwood awarded South Australian of the Year
12/11/15
PNV Appendix 3B
12/11/15
PNV Appendix 3B
11/11/15
PNV Annual Report to shareholders
29/10/15
PNV Notice of Annual General Meeting/Proxy Form
29/10/15
PNV Company Secretary Appointment/Resignation
27/10/15
PNV Final Patient Recruited in Adelaide Burn Trial
20/10/15PRICE SENSITIVE
PNV PolyNovo Awarded BARDA Contract for Burns Trial
29/09/15PRICE SENSITIVE
PNV Trading Halt
28/09/15PRICE SENSITIVE
PNV Investor Presentation
01/09/15
PNV Appendix 4G
21/08/15
PNV App 4E / Full Year Statutory Accounts
20/08/15PRICE SENSITIVE
PNV Financial Result Guidance
14/08/15PRICE SENSITIVE
PNV Appendix 3B
06/08/15
PNV CEO Long Term Incentives
06/08/15
PNV Change in substantial holding
04/08/15
PNV Change in substantial holding
04/08/15
PNV PNV New timeline for FDA 510(k)
02/07/15
PNV Clinical Paper on Patient follow up of PolyNovo BTM
01/07/15PRICE SENSITIVE
PNV Change of Director's Interest Notice
17/06/15
PNV PolyNovo Burn Trial Receives Ethics Approval at The Alfred
15/06/15PRICE SENSITIVE
PNV CE Mark Clinical Trial for BTM in Severe Burns
08/05/15PRICE SENSITIVE
PNV Settlement of AOD9604 Sale
07/05/15
PNV PolyNovo Divests AOD9604
30/04/15PRICE SENSITIVE
PNV Half Yearly Report and Accounts
23/02/15PRICE SENSITIVE
PNV Half Year Financial Result Guidance
17/02/15PRICE SENSITIVE
PNV New Chief Executive Officer and Head of Regulatory Affairs
13/02/15PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
$1.99 		Change
-0.040(1.97%) 		Mkt cap ! $1.699B
Open High Low Value Volume
$2.04 $2.05 $1.96 $1.644M 824.2K

Buyers (Bids)

No. Vol. Price($)
1 4210 $1.97
 

Sellers (Offers)

Price($) Vol. No.
$1.99 3578 2
View Market Depth
Last trade - 16.10pm 21/11/2024 (20 minute delay) ?
Last
$1.98 		  Change
-0.040 ( 2.41 %)
Open High Low Volume
$2.04 $2.05 $1.96 197212
Last updated 15.59pm 21/11/2024 ?
PNV (ASX) Chart

Top Stories

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Alcidion inks deal with Vic health provider Peninsula for use of Miya Precision tech Alcidion Group Ltd has signed a contract worth $3.7M to enable use of its Miya Precision platform by users of Peninsula Health entities
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.